JP7650795B2 - Ｂ細胞を活性化するｃｄ７３抗体 - Google Patents

Ｂ細胞を活性化するｃｄ７３抗体 Download PDF

Info

Publication number
JP7650795B2
JP7650795B2 JP2021523933A JP2021523933A JP7650795B2 JP 7650795 B2 JP7650795 B2 JP 7650795B2 JP 2021523933 A JP2021523933 A JP 2021523933A JP 2021523933 A JP2021523933 A JP 2021523933A JP 7650795 B2 JP7650795 B2 JP 7650795B2
Authority
JP
Japan
Prior art keywords
antibody
aspects
cells
kabat
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512901A5 (enExample
JP2022512901A (ja
Inventor
グリフィン，エミリー・ピッチョーネ
バギー，ジョーセフ
ホットソン，アンドリュー
Original Assignee
コーバス・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーバス・ファーマシューティカルズ・インコーポレイテッド filed Critical コーバス・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2022512901A publication Critical patent/JP2022512901A/ja
Publication of JP2022512901A5 publication Critical patent/JP2022512901A5/ja
Application granted granted Critical
Publication of JP7650795B2 publication Critical patent/JP7650795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021523933A 2018-11-05 2019-11-05 Ｂ細胞を活性化するｃｄ７３抗体 Active JP7650795B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862756065P 2018-11-05 2018-11-05
US62/756,065 2018-11-05
US201962848524P 2019-05-15 2019-05-15
US62/848,524 2019-05-15
US201962855601P 2019-05-31 2019-05-31
US62/855,601 2019-05-31
PCT/US2019/059933 WO2020097127A2 (en) 2018-11-05 2019-11-05 B-cell activating cd73 antibodies

Publications (3)

Publication Number Publication Date
JP2022512901A JP2022512901A (ja) 2022-02-07
JP2022512901A5 JP2022512901A5 (enExample) 2022-11-10
JP7650795B2 true JP7650795B2 (ja) 2025-03-25

Family

ID=70612455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523933A Active JP7650795B2 (ja) 2018-11-05 2019-11-05 Ｂ細胞を活性化するｃｄ７３抗体

Country Status (9)

Country Link
US (1) US20220242963A1 (enExample)
EP (1) EP3880710A4 (enExample)
JP (1) JP7650795B2 (enExample)
KR (1) KR20210100099A (enExample)
AU (1) AU2019377454A1 (enExample)
CA (1) CA3118706A1 (enExample)
IL (1) IL282852A (enExample)
MX (1) MX2021005248A (enExample)
WO (1) WO2020097127A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4084870A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
BR112022020256A2 (pt) * 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
TWI900705B (zh) * 2020-12-11 2025-10-11 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
CN119317449A (zh) * 2022-03-14 2025-01-14 上海华奥泰生物药业股份有限公司 抗体药物偶联物及其应用
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100670A1 (en) 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
WO2018187512A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340569B1 (en) * 1997-11-12 2002-01-22 University Of Pittsburgh Monoclonal antibody and antigens specific therefor and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100670A1 (en) 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
WO2018187512A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Carl M. Hay et al.，Targeting CD73 in the tumor microenvironment with MEDI9447，Oncoimmunology，2016年，Vol.5, No.8，Article Number: E1208875, Pages 1-10
Giovanni Forte et al.，Inhibition of CD73 Improves B Cell-Mediated Anti-Tumor Immunity in a Mouse Model of Melanoma，The Journal of Immunology，2012年，Vol.189, No.5，Pages 2226-2233
Zenichiro Saze, et al.，Adenosine production by human B cells and B cell-mediated suppression of activated T cells，BLOOD，2013年，Vol.122, No.1，Pages 9-18

Also Published As

Publication number Publication date
MX2021005248A (es) 2021-08-11
WO2020097127A3 (en) 2020-06-18
IL282852A (en) 2021-06-30
WO2020097127A2 (en) 2020-05-14
EP3880710A4 (en) 2022-07-27
CA3118706A1 (en) 2020-05-14
KR20210100099A (ko) 2021-08-13
JP2022512901A (ja) 2022-02-07
US20220242963A1 (en) 2022-08-04
EP3880710A2 (en) 2021-09-22
AU2019377454A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
KR20210100099A (ko) B 세포 활성화 cd73 항체
US20180177847A1 (en) Compositions and methods for modulating pro-inflammatory immune response
EP3813881A2 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
KR102810368B1 (ko) 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
US20230414540A1 (en) Combination of immunotherapy with local chemotherapy for the treatment of malignancies
WO2011079902A2 (en) Biological materials and uses thereof
WO2015048312A1 (en) Methods for treating hematologic cancers
JP2025032075A (ja) Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体
US20240426825A1 (en) Use of tctp as biomarker for predicting efficacy, prognosis of immunotherapy or resistance thereto, and target of immunotherapy for enhancing efficacy
JP2022512922A (ja) キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法
US20260116986A1 (en) Epo receptor agonists and antagonists
CN106659758A (zh) 用于免疫调节的组合物和方法
US20230034677A1 (en) Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
EP4399330A1 (en) Gene fusions in sarcoma
EP3965750A1 (en) Cancer stratification and treatment based on inhibition of nod-2
WO2012074842A2 (en) Compositions and methods for treating neoplasia
WO2022081869A1 (en) Compositions and methods for overcoming dr5-induced immune evasion by solid tumors
US20240368605A1 (en) Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
US9150929B2 (en) Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
JP2025526399A (ja) Ｂ細胞特異的ｍＡｂ－ｓｉＲＮＡコンジュゲートは筋無力症を改善する
WO2024148402A1 (en) A method of preparing cells for adoptive cell therapy
EP2765141A1 (en) Compositions comprising agents that inhibit neuroplilin and tolloid like 2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250312

R150 Certificate of patent or registration of utility model

Ref document number: 7650795

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150